Oxford Endovascular Raises £8M for OXIFLOW Innovation
Oxford Endovascular Secures £8M in Series A Funding to Revolutionize Brain Aneurysm Treatment
Oxford Endovascular, a pioneering medtech startup established in 2015, has successfully raised £8M in a Series A funding round. This strategic financial boost will empower the British company to advance its groundbreaking technology, OXIFLOW, aimed at mitigating brain hemorrhages by treating at-risk intracranial aneurysms. Unlike conventional flow-diverters, OXIFLOW's revolutionary design enables precise and dependable placement, thus minimizing potential complications that may lead to adverse events.
The company's unwavering dedication to collaboration with regulators, physicians, and industry experts underscores their commitment to bringing this life-transforming technology to the market. In addition to this recent funding, Oxford Endovascular has also secured financial support from Horizon Europe, Innovate UK, and the EU's EIT-funded Covid rescue programme.
Key Takeaways
- Oxford Endovascular secures £8M in Series A funding for brain aneurysm technology
- OXIFLOW, a laser-cut Nitinol flow-diverter stent, diverts blood flow away from aneurysms at risk of rupture
- OXIFLOW's unique design allows for more accurate and reliable placement, minimizing complications
- Up to 35% of existing device placements for treating brain aneurysms have complications leading to adverse events
- Funding will drive product development towards clinical studies and human trials in the near future
Analysis
The successful £8M Series A funding secured by Oxford Endovascular signifies a significant leap forward towards accelerating clinical trials for OXIFLOW, an innovative device offering a proactive approach to addressing brain aneurysms. This substantial financial injection, in conjunction with the support from Horizon Europe, Innovate UK, and EIT, exemplifies the escalating interest in cutting-edge medtech solutions. The implications are profound, as the potential success of OXIFLOW could substantially reduce the occurrences of brain hemorrhages, thereby benefiting patients, healthcare facilities, and healthcare systems at large. Moreover, this accomplishment is poised to stimulate further investment in the European medtech sector and potentially inspire similar groundbreaking innovations on a global scale.
Did You Know?
- Medtech startup: Oxford Endovascular is a prime example of a medtech startup, amalgamating technology and medical expertise to develop pioneering devices and solutions aimed at enhancing healthcare and medical procedures, with a specific focus on treating intracranial aneurysms.
- Series A funding: This stage of venture capital financing enables companies to procure external capital to support growth and product development. Oxford Endovascular's acquisition of £8M in this round will significantly propel their progress towards clinical studies and human trials for their breakthrough device, OXIFLOW.
- Flow-diverter stent (OXIFLOW): OXIFLOW, a laser-cut Nitinol stent, represents a groundbreaking medical device designed to conform to a patient's blood vessels. By diverting blood flow away from at-risk aneurysms, this innovative technology has the potential to mitigate complications and adverse events, addressing the crucial need in this field and offering immense value to patients and medical professionals alike.